Sun, Feb 1, 2015, 7:38 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aradigm Corporation Message Board

arql07 9 posts  |  Last Activity: Jan 22, 2015 4:47 PM Member since: Jun 19, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • arql07 arql07 Jan 22, 2015 4:47 PM Flag

    I'm sorry, but I don't connect the dot's. Please explain, thanks.

  • Reply to

    We have life

    by billyteex1 Jan 22, 2015 1:10 PM
    arql07 arql07 Jan 22, 2015 4:02 PM Flag

    I would like to see more follow through. If they ever get funded, this could jump to the .05 range.

  • Reply to


    by doctorbobphd Dec 6, 2014 2:20 AM
    arql07 arql07 Dec 6, 2014 1:22 PM Flag

    The 510 pathway they took was stupid. They wasted years going this route. First the PEMF was a Class 3 proposition. So all those early years work, was a total waste. They would still need a prescription to sell anything. Management was inexperienced and that shows. Now, why has this taken so long to reach a decision.

    They would have been much better off, conducted trials like any medical device company. But the short cut they took, actually was the long way. They even got warning letters. This is why everyone hates them. Management is a screw up. They took short cuts that don't work. I also blame early investors, constant pestering the FDA.

    Now 6B shares in dilution and we wait. Lucky for some of us, we have traded this. Taking advantage of some situations. Long ago, I figured we have a good product, but VERY poor management. This is what happens, when the pathway is not thought out correctly. Today they sell just $250K a quarter. That they have to give away product and use unscientific surveys. I used the product and swear by it. I believe the Whelans would have been smarter to have brought in someone with experience and paid them a 500M shares in 2009. We would be over the hump. This CEO was a idiot and no one can deny that. Smart to see a opportunity, dumb in what it takes to get it through the hurdles. Well he's learned using your funds. Every stinken penny of them.

    Sometimes you have to admit you invested for the right reasons, just the wrong team. Now on a better note, I feel we see something this week on classifications. Lucky for BIEL, there's other companies also looking for this classification. But 5 years ago, they should have realized it was fruitless to seek a 510 pathway on a class 3 medical device. Too many years wasted. All because of one man's high opinion of himself.

  • Reply to


    by dbtunr Nov 16, 2014 11:00 AM
    arql07 arql07 Nov 17, 2014 7:42 AM Flag


    I have an important question, that only you are qualified to answer. Can I still order off the breakfast menu?

  • Reply to

    Capitulation Continues

    by grandslammer222 Nov 6, 2014 9:56 AM
    arql07 arql07 Nov 6, 2014 10:05 AM Flag

    But, you make it work for you. I sold at $3.50. Just bought it back this morning, pocketing a bunch. Grandslammer, you are bragging that you didn't buy it at $1.50. Think before you post.

  • Reply to

    $6.2B requested to fight Ebola

    by billyteex1 Nov 6, 2014 6:59 AM
    arql07 arql07 Nov 6, 2014 9:54 AM Flag

    1.2M sitting on the bid this morning. Clayton, time to do something right for investors. Enough is enough. Shift the investment paradigm here. The IOBS should be in every hospital, airport and country.

  • Reply to

    Agreement Prediction...

    by grueman1 Nov 3, 2014 2:04 PM
    arql07 arql07 Nov 3, 2014 2:45 PM Flag

    Is dbtunr pretending he own shares.

  • Reply to

    Seas were rough that day

    by arql07 Nov 3, 2014 2:31 PM
    arql07 arql07 Nov 3, 2014 2:41 PM Flag

    That's who I copied it from. I've known billy for years. Thought he would laugh at it. Dbtunr, you have to admit, you missed the boat here.

  • Like an old man returning soup in a deli.

    Stay with this one. All cash offer or stock.

7.45-0.13(-1.72%)Jan 30 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.